Lyell Immunopharma Investor Relations Material
Latest events
M&A Announcement
Lyell Immunopharma
Q1 2025
13 May, 2025
Q4 2024
11 Mar, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Lyell Immunopharma Inc
Access all reports
Lyell Immunopharma Inc is a biotechnology company focused on developing cell-based immunotherapies for cancer treatment. The company specializes in genetically engineering T cells to enhance their persistence, potency, and functionality against solid tumors. Lyell Immunopharma conducts research and development activities in collaboration with academic and industry partners. The company is headquartered in South San Francisco, California, and its shares are listed on the NASDAQ.
Key slides for Lyell Immunopharma Inc
43rd Annual J.P. Morgan Healthcare Conference 2025
Lyell Immunopharma Inc
M&A Announcement
Lyell Immunopharma Inc
Latest articles
)
Pershing Square Capital Management: Conviction, Reinvention, and Contrarian Investing
Pershing Square Capital Management has grown into a top-tier hedge fund through reinvention, conviction, and focus on long-term value creation.
2 Jul 2025
)
Eli Lilly: The Pharma Giant Behind Mounjaro and Zepbound
Eli Lilly's journey from insulin pioneer to global pharma giant, leading innovation in diabetes, obesity, and the future of metabolic health.
30 Jun 2025
)
500 Years of Craft, One Family Legacy: Beretta Holding's Global Expansion
How Beretta Holding managed to transform from a 16th-century gun barrel producer into a global industrial group while preserving 500 years of legacy.
27 Jun 2025
Ticker symbol
LYEL
Country
🇺🇸 United States